MINUTES OF THE PEDIATRIC ADVISORY COMMITTEE (PAC)

The public meeting was convened 8:30 a.m. to 12:45 p.m. on September 12, 2017

Members Present (Voting)	**Temporary Voting Members (Voting Consultants)**
Kelly Wade, MD, PhD *(Acting Chair)*	Jeffrey Campbell, MD, MS
David Callahan, MD	Amy Celento, BS
Mary Cataletto, MD, FAAP	Gwenyth Fischer, MD
Melody Cunningham, MD	James McGough, MD
Robert Dracker, MD, MHA, MBA, CPI	Kathleen Neville, MD, MS, FAAP, FCCP
Peter Havens, MD, MS	
Sarah Hoehn, MD, MBe, FAAP	
Bridgette Jones, MD	
Wael Sayej, MD	
Christy Turer, MD, MHS, FAAP, FTOS	
Michael G. White, MD, PhD, FACC, FAAP	
Non-Voting Members	**Designated Federal Official (DFO)**
Bridgette Jones, MD	Marieann Brill, MBA, RAC, MT (ASCP)
Ronald Portman, MD	

U.S. Food and Drug Administration (FDA) Participants

Office of Pediatric Therapeutics	**CDER OSE**:	**CDRH**
Judith Cope, MD, MPH	Vicky Chan, PharmD, MD	George Aggrey, MD, MPH
Robert "Skip" Nelson, MD, PhD	Robert Levin, MD	Chin-Hsin K. (Jenny) Liu, RN, BSN, MSN
Ann McMahon, MD, MS	Karen Long, PharmD	Courtney Lias, PhD
LCDR Kenneth Quinto, MD, MPH	Shekhar H. Mehta, PharmD, MS	Lauren Min, MPH
	LT Ofir Noah Nevo, PharmD, BCPP	Vasum Peiris, MD, MPH, FAAP, FACC, FASE
CDER DPMH	LT Travis Ready, PharmD	Catherine Ricketts, RN, BSN
John Alexander, MD, MPH		Dora Vega, MD, PhD
Ethan Hausman, MD	**CDER Division**	Priya Venkataraman-Rao, MD
Yeruk (Lily) Mulugeta, MD	Teresa, Buracchio, MD	
Carolyn Yancey, MD	Natalie Getzoff, MD	
	Marc Stone, MD	

Welcome and Introductory Remarks

- Marieann Brill, Designated Federal Official (DFO), Pediatric Advisory Committee, Office of Pediatric Therapeutics, Office of Special Medical Programs, US Food and Drug Administration (FDA)
- Kelly Wade, MD, PhD, Acting Chair of the Pediatric Advisory Committee

Office of Pediatric Therapeutics: Presentation: State of the PAC – Robert "Skip" Nelson, MD, PhD

This presentation summarized the past and ongoing process for mandated pediatric post-market safety reviews to the PAC, starting with abbreviated reviews and transitioning to web-posting for CDER and CBER products. A proposal of web-posting for annual device reviews that do not have new safety concerns was also presented, and will be implemented in Spring 2018.

Open Public Hearing
An opening statement was read by the Marieann Brill, DFO. One presentation was given by Mr. Jack Mitchell, Director of Health Policy, from the National Center for Health Research (NCHR) related to the topic of Abilify.

Center for Drug Evaluation and Research (CDER): Standard Review of Adverse Event Presentations

Abilify (aripiprazole) – Carolyn Yancey, MD
FDA did not identify any new safety signals, and recommended to continue ongoing post-marketing safety monitoring. The PAC discussed the limitations of adverse event data collected in regards to rates of suicidality, serious metabolic disorders, and weight gain. One PAC member noted that some pediatric patients with autism may not be able to communicate about suicidal ideation.

- The Committee concurred with the FDA plan to continue ongoing post-marketing safety monitoring. (Yes - 12; No - 2; Abstained - 0)

Keppra and Keppra XR – Lily Mulugeta, MD
FDA did not identify any new safety signals, and plans to monitor for cardiovascular adverse events, rhabdomyolysis, and encephalopathy in all patient populations. FDA recommended to continue ongoing post-marketing safety monitoring.

- The Committee concurred with the FDA plan to continue ongoing post-marketing safety monitoring. (Yes - 14; No – 0; Abstained - 0).

Center for Devices and Radiological Health (CDRH): Annual Post-Market Humanitarian Device Exemption (HDE) Reviews:

Contegra Pulmonary Valved Conduit – Dora Vega, MD, PhD
The annual review of the Medical Device Reports (MDRs) identified a case of conduit replacement for unclear reason(s). The FDA believes that currently there is insufficient information to determine if this was a case of tracheal compression due to the device and has requested additional information from the manufacturer. FDA recommended to continue device surveillance and to report again to the PAC in 2018.

- The Committee concurred with the FDA plan to continue device surveillance and report to the PAC in 2018. (Yes - 14; No - 0; Abstained - 0)

Enterra™ Therapy System – Dora Vega, MD, PhD
The annual review did not identify any new or unexpected risks for the pediatric population. FDA recommended to continue device surveillance and to report again to the PAC in 2018.

- The Committee concurred with the FDA plan to continue device surveillance and report to the PAC in 2018. (Yes - 14; No - 0; Abstained - 0)

Elana Surgical Kit Humanitarian Use Device (HUD) – Dora Vega, MD, PhD
FDA reported that there was no reported use, sales, or new publications in the last year. The post approval study has been put on hold due to non-use in the United States, and would resume if there are any reported sales and use. FDA recommended to continue device surveillance and to report again to the PAC in 2018.

- The Committee concurred with the FDA plan to continue device surveillance and report to the PAC in 2018. (Yes - 14; No - 0; Abstained - 0)

Pleximmune – Courtney Lias, PhD
FDA did not identify any new or unexpected safety concerns for the pediatric population. FDA recommended to continue device surveillance and to report again to the PAC in 2018.

- The Committee concurred with the FDA plan to continue device surveillance and report to the PAC in 2018. (Yes - 14; No - 0; Abstained - 0)

Berlin Heart EXCOR – Vasum Peiris, MD, MPH
In June 2017, the Berlin Heart EXCOR was approved following a Premarket Approval (PMA) application, and no longer is a pediatric HDE. Annual safety reviews for the PAC are no longer required.

Office of Pediatric Therapeutics: Presentation - Kidnet Trajectory: Where have we been? Where should we go? – Ann McMahon, MD, MS

This presentation provided updated information on postmarket studies using Kidnet, a network of pediatric hospitals coordinated by FDA. Data from pediatric intensive care units (ICUs) was reviewed for adverse events in two studies, one with octreotide and proton pump inhibitors and another with the use of fentanyl and azithromycin. A third study evaluated renal adverse effects of intravenous acyclovir in neonates.

Committee Discussion: The committee discussed the use of electronic medical record (EMR) systems and expanded databases to collect information from a larger cohort of pediatric hospitals. One member of the PAC noted that other important pediatric safety issues such as contraceptive use and bone health might be elucidated with a larger database. Another alternative would be to explore some of the adverse events noted in the the PAC safety reviews, such as Abilify and cerebrovascular accidents. It was noted, however, that the Kidnet network was insufficiently powered to explore these questions adequately.

Adjournment
Kelly Wade, MD, PhD, Acting Chair

FINAL APPROVAL:

/s/
Marieann R. Brill, MBA, RAC, MT(ASCP)
Designated Federal Officer, PAC

/s/
Kelly Wade, MD, PhD
Acting Chair, PAC